Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

被引:49
|
作者
Lizan, Luis [1 ]
Comellas, Marta [1 ]
Paz, Silvia [1 ]
Luis Poveda, Jose [2 ]
Meletiche, Dennis M. [3 ]
Polanco, Carlos [4 ]
机构
[1] Outcomes 10, Castellon de La Plana, Spain
[2] Hosp Univ La Fe, Valencia, Spain
[3] EMD Serono Inc, Rockland, MA USA
[4] Merck SL, Madrid, Spain
来源
PATIENT PREFERENCE AND ADHERENCE | 2014年 / 8卷
关键词
multiple sclerosis; adherence; satisfaction; delivery devices; costs; DISEASE-MODIFYING THERAPIES; MEDICATION ADHERENCE; TREATMENT PREFERENCES; RHEUMATOID-ARTHRITIS; MANAGEMENT PROGRAM; UNMET NEEDS; PREVALENCE; RELAPSE; IMPACT; DRUGS;
D O I
10.2147/PPA.S67253
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Treatment adherence is one of the key factors for achieving optimal clinical outcomes. In order to assess costs related to adherence to, and persistence and compliance with, disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS), a narrative review of the literature was performed. Satisfaction with and preference for DMTs and their delivery devices were also assessed, as both can have an influence on patients' adherence and persistence. Methods: Electronic databases (MEDLINE, PubMed, Google Scholar, congress proceedings) were searched to identify publications analyzing MS costs related to adherence, persistence, satisfaction, and preferences for MS treatments. Bibliographic references were hand searched. English or Spanish studies published between January 2007 and January 2013 were selected. Results: A total of 398 titles were identified, of which 12 met the inclusion criteria. Six studies evaluated the impact of adherence, persistence, and compliance on treatment costs; four publications analyzed satisfaction with DMTs; and two assessed treatment preferences based on attributes of the delivery device. Increased adherence and persistence were associated with better clinical outcomes, leading to lower relapse risk (odds ratio [OR]: 0.71; 95% confidence interval [CI]: 0.59-0.85) and a decrease in health care resource use, such as MS-related hospitalizations (OR: 0.63; 95% CI: 0.47-0.83) and emergency department visits (OR: 0.80; 95% CI: 0.60-1.07). This reduction in resource use led to a patient/year total cost reduction (excluding DMT costs) of up to 22%. Conclusion: This review highlights the importance of ensuring adequate adherence in MS patients through treatments and devices better tailored to patients' needs that could enhance clinical outcomes and reduce MS costs. Understanding the factors underlying satisfaction and compliance with treatment and patients' preference for certain therapies could help in the development of strategies that can improve adherence.
引用
收藏
页码:1653 / 1664
页数:12
相关论文
共 50 条
  • [1] Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes
    Dirziuviene, Birute
    Mickeviciene, Dalia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
  • [2] Review: Patient-reported outcomes in multiple sclerosis care
    D'Amico, Emanuele
    Haase, Rocco
    Ziemssen, Tjalf
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 61 - 66
  • [3] Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis
    Jakimovski, Dejan
    Wicks, Taylor R.
    Bergsland, Niels
    Dwyer, Michael G.
    Weinstock-Guttman, Bianca
    Zivadinov, Robert
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2023, 13 : 21 - 32
  • [4] Cognitive reserve and patient-reported outcomes in multiple sclerosis
    Schwartz, Carolyn E.
    Snook, Erin
    Quaranto, Brian
    Benedict, Ralph H. B.
    Vollmer, Timothy
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (01) : 87 - 105
  • [5] Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence
    Sadigh, Gelareh
    Lava, Neil
    Switchenko, Jeffrey
    Duszak, Richard, Jr.
    Krupinski, Elizabeth A.
    Meltzer, Carolyn
    Hughes, Danny
    Carlos, Ruth C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 453 - 464
  • [6] Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study
    Lerede, Annalaura
    Rodgers, Jeff
    Middleton, Rod M.
    Hampshire, Adam
    Nicholas, Richard
    BRAIN COMMUNICATIONS, 2023, 5 (04)
  • [7] Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis
    Healy, Brian C.
    Zurawski, Jonathan
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie, I
    QUALITY OF LIFE RESEARCH, 2022, 31 (06) : 1799 - 1805
  • [8] Patient perspectives on patient-reported outcomes in multiple sclerosis treatment trajectories: A qualitative study of why, what, and how?
    Westergaard, Katrine
    Skovgaard, Lasse
    Magyari, Melinda
    Kristiansen, Maria
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [9] Use of an Online Community to Develop Patient-Reported Outcome Instruments: The Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)
    Wicks, Paul
    Massagli, Michael
    Kulkarni, Amit
    Dastani, Homa
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2011, 13 (01) : 117 - 128
  • [10] Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart® : the CORE study
    Zecca, Chiara
    Disanto, Giulio
    Muhl, Sarah
    Gobbi, Claudio
    BMC NEUROLOGY, 2017, 17